This included nivolumab and anti-LAG3 antibodies (another co-inhibitory protein), and combination with nivolumab, ipilimumab and cobimetanib (MEK inhibitor) and nivolumab with daratumumab (anti-CD38 antibody)—a protein previously associated with tumour cells of myeloma. The gene discussed is MAP2K7; the disease is neoplasm.